Saxenda
Teva Launches First Generic GLP-1 for Weight Loss Amid Ongoing Market Developments
generic GLP-1; Teva; liraglutide; Saxenda; FDA approval; weight loss drugs
FDA Requests Eli Lilly and Novo Nordisk to Remove Suicide Warnings from GLP-1 Drug Labels
FDA; GLP-1; suicide warnings; Eli Lilly; Novo Nordisk; Wegovy; Zepbound; Saxenda
Teva Launches First Generic GLP-1 Weight-Loss Drug in the US
Teva; GLP-1; generic; weight loss; liraglutide; FDA approval; Saxenda; obesity treatment; United States
Novo Nordisk’s Saxenda Demonstrates Significant Weight Loss in Children Aged 6-12 in Phase III Trial
Saxenda, Novo Nordisk, pediatric obesity, weight loss, Phase III trial, EASD24
Medicare Coverage Gap Linked to Reduced Prescription Rates for GLP-1 Weight Loss Drugs
GLP-1 drugs, Medicare coverage gap, Lower prescription rates, Obesity treatment, Semaglutide (Wegovy), Tirzepatide (Mounjaro), Liraglutide (Saxenda), Healthcare costs, Truveta study